NumerixS Investment Technologies Inc bought a new stake in shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 9,000 shares of the biopharmaceutical company’s stock, valued at approximately $125,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of SGMO. BlackRock Inc. grew its stake in Sangamo Therapeutics by 20.8% during the second quarter. BlackRock Inc. now owns 8,083,121 shares of the biopharmaceutical company’s stock valued at $114,780,000 after acquiring an additional 1,391,067 shares in the last quarter. Prudential Financial Inc. grew its stake in shares of Sangamo Therapeutics by 331.9% in the 1st quarter. Prudential Financial Inc. now owns 505,536 shares of the biopharmaceutical company’s stock worth $9,605,000 after buying an additional 388,480 shares in the last quarter. Wasatch Advisors Inc. grew its stake in shares of Sangamo Therapeutics by 9.9% in the 2nd quarter. Wasatch Advisors Inc. now owns 4,058,167 shares of the biopharmaceutical company’s stock worth $57,626,000 after buying an additional 365,186 shares in the last quarter. Handelsbanken Fonder AB purchased a new position in shares of Sangamo Therapeutics in the 2nd quarter worth $5,069,000. Finally, Wells Fargo & Company MN grew its stake in shares of Sangamo Therapeutics by 42.2% in the 2nd quarter. Wells Fargo & Company MN now owns 789,981 shares of the biopharmaceutical company’s stock worth $11,218,000 after buying an additional 234,346 shares in the last quarter. 63.97% of the stock is owned by institutional investors.

A number of equities analysts have commented on the stock. BidaskClub raised shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, June 20th. ValuEngine cut shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, September 6th. Zacks Investment Research raised shares of Sangamo Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 24th. Wedbush reissued a “hold” rating and issued a $9.00 price objective on shares of Sangamo Therapeutics in a research note on Tuesday, July 24th. Finally, Cowen reissued a “buy” rating on shares of Sangamo Therapeutics in a research note on Monday, July 23rd. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $21.00.

Shares of NASDAQ:SGMO opened at $14.45 on Thursday. Sangamo Therapeutics Inc has a 52 week low of $11.30 and a 52 week high of $27.50. The company has a debt-to-equity ratio of 0.07, a current ratio of 7.24 and a quick ratio of 7.24.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.02). The firm had revenue of $21.42 million during the quarter, compared to the consensus estimate of $21.43 million. Sangamo Therapeutics had a negative return on equity of 26.36% and a negative net margin of 105.65%. Sangamo Therapeutics’s revenue was up 159.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.17) EPS. equities research analysts predict that Sangamo Therapeutics Inc will post -0.69 EPS for the current fiscal year.

In other news, Director H Stewart Parker bought 2,000 shares of the stock in a transaction dated Friday, September 7th. The stock was purchased at an average price of $13.52 per share, for a total transaction of $27,040.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Edward R. Conner sold 5,000 shares of the firm’s stock in a transaction dated Thursday, September 6th. The stock was sold at an average price of $14.17, for a total transaction of $70,850.00. The disclosure for this sale can be found here. Insiders sold a total of 30,000 shares of company stock valued at $446,250 in the last 90 days. Company insiders own 1.20% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

Further Reading: How Do You Calculate Return on Investment (ROI)?

Want to see what other hedge funds are holding SGMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sangamo Therapeutics Inc (NASDAQ:SGMO).

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.